MedCity News

Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers.

Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology.

digital health fundraising Coverage

Celcuity Coverage

For years, the healthcare industry treated data collection as the main challenge. The next phase is about interpretation, coordination, and operational usability. The organizations that solve this problem well will be those that can turn fragmented information into faster, clearer, and more actionable decisions.

If we do not get this right, we may inadvertently cause a new sarcopenia epidemic while congratulating ourselves on solving obesity.

This is not an argument against capital in independent medicine. Practices need infrastructure, and physicians have legitimate reasons to seek liquidity. It is an argument that the exit stage carries a risk this market has not yet priced.

Eli Lilly's AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley's lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant depression.

CMS' proposed 2027 Physician Fee Schedule would bar Medicare payment for remote monitoring services delivered by third-party vendors, following OIG reports that flagged widespread fraud in the space.

The House Ways and Means Committee unanimously advanced a bill to reform Medicare Advantage prior authorization requirements.